Short steroid treatment for lung infection from PCP in HIV
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study tests whether short-term steroid treatment helps adults with a specific lung infection (PCP) that happens with HIV/AIDS. It compares outcomes in people who start steroids soon after admission while also taking standard PCP antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old
- Have lung test results at admission showing moderate or severe PCP
- Be taking the standard PCP antibiotic (trimethoprim/sulfamethoxazole) soon after admission at the study dosing
- Start steroid treatment within the first 48 hours after admission
- Have no long-term (chronic) lung disease and have an APACHE score under 20
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different lengths of steroid treatment for people with severe Pneumocystis pneumonia (a serious lung infection). If you have improved enough by day 10 to breathe without oxygen, the study will see if stopping steroids sooner is as safe and effective as continuing them.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
This trial tests whether giving steroids (anti-inflammatory medicines) to people with a severe lung infection called Pneumocystis pneumonia (PJP) can improve outcomes. It is for patients who are in the ICU and do not have HIV, which is a different group than typical PJP patients.
This study looks at how well the antibiotic combination TMP-SMX works for treating a type of lung infection called Pneumocystis pneumonia in people who do not have HIV. If you have this infection and are starting TMP-SMX, the study will follow your progress to see how safe and effective this treatment is.
This study tests whether giving a personalized dose of steroids (anti-inflammatory medicine) early can help people with severe pneumonia-related breathing failure recover faster. It compares different steroid doses based on your body's inflammation and immune response.
Hear when a new Pneumocystis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.